AMLN: Summary for Amylin Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, February 9, 2010, 10:36am EST - Canadian Markets close in 5 hours and 24 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Amylin Pharmaceuticals Inc. (AMLN)

At 10:20 EST: 17.56 USD

0.23 (1.33%)

MORE ON AMLN

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Amylin Pharmaceuticals, Inc. (NasdaqNM:AMLN) Delayed quote data

Last Trade:	17.56 USD
Trade Time:	10:20AM EST
Change:	0.23 (1.33%)
Prev Close:	17.33
Open:	17.51
Bid:	17.56 x 1100
Ask:	17.57 x 1200
1y Target Est:	46.29

Day's Range:	17.50 - 17.73
52wk Range:	7.89 - 19.99
Volume:	272,345
Avg Vol (3m):	3,218,870
Market Cap:	2.49B
P/E (ttm):	N/A
EPS (ttm):	-1.47
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add AMLN to Portfolio

Download Data

HEADLINES

•	Biotech ETFs Immune To Broad Selling
	Investor's Business Daily (Mon 5:34pm)

•	Alkermes Retains Neutral Rec
	Zacks.com (Mon 3:07pm)

•	AMYLIN PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Fri, Feb 5)

•	Alkermes Testing its Version of Popular Schizophrenia Drug
	at TheStreet.com (Thu, Feb 4)

•	Alkermes Testing Schizophrenia Drug
	at TheStreet.com (Thu, Feb 4)

•	Novo Nordisk Has High Hopes for Diabetes Blockbuster
	at Seeking Alpha (Wed, Feb 3)

•	The Shaky State Of California Biopharma
	at CNBC (Tue, Feb 2)

•	Eli Lilly and the Depression-Diabetes Circle
	at Minyanville.com (Tue, Feb 2)

•	UPDATE - Novo Nordisk ups outlook, Q4 EBIT beats consensus
	at Reuters (Tue, Feb 2)

•	2-Star Stocks Poised to Plunge: MannKind?
	at Motley Fool (Tue, Feb 2)

•	Weekly Street Sentiment: Mostly Cloudy with a Chance of Sunshine
	at Seeking Alpha (Tue, Feb 2)

•	Monday Options Recap
	at Seeking Alpha (Mon, Feb 1)

•	PREVIEW-Novo Nordisk Q4 seen down but 2010 rosier
	at Reuters (Mon, Feb 1)

•	Novo Nordisk Awaits China Approval of Diabetes Treatment
	at Seeking Alpha (Sun, Jan 31)

•	[$$] 13D Filings
	at Barrons.com (Sat, Jan 30)

More Headlines for AMLN...

ANALYST

EPS Est (next year) (Dec-08) :	-1.91
EPS Est (in 2 years) (Dec-09) :	-1.24
Avg Rec (current)*:	2.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•